Please assess the completion status of the following clinical trial:

Trial Title: SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female, age greater than or equal to 18 years.~* Confirmed chronic HCV infection.~* Subjects will have cirrhosis status assessment; liver biopsy may be required.~* Genotype 2 subjects must have cirrhosis of the liver to be eligible.~* Treatment-naive or prior treatment failure to ≥12 weeks of an interferon- based regimen that was not discontinued prematurely due to an adverse event~* Infection with HCV genotype 2 or 3 as determined at Screening~* Body mass index (BMI) greater than or equal to 18 kg/m\^2~* Screening laboratory values within predefined thresholds.~* Liver imaging (e.g., ultrasound) within 6 months of Baseline/Day 1 is required in cirrhotic patients to exclude hepatocellular carcinoma (HCC). In the event of intrahepatic lesions, triple phase CT scan or MRI should be performed to exclude HCC.~* Subject must be of generally good health as determined by the Investigator.~Key Exclusion Criteria:~* Prior use of any other inhibitor of the HCV nonstructural protein (NS)5B polymerase~* Pregnant or nursing female or male with pregnant female partner~* History of any other clinically significant chronic liver disease.~* HIV or chronic hepatitis B virus (HBV) infection.~* Malignancy with the exception of certain resolved skin cancers.~* Chronic use of systemically administered immunosuppressive agents.~* Clinically-relevant drug or alcohol abuse.~* History of solid organ transplantation.~* Current or prior history of clinical hepatic decompensation.~* History of clinically-significant illness or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol.~* Known hypersensitivity to interferon, RBV, the study investigational medicinal product, the metabolites, or formulation excipients.~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF+RBV 16 weeks (Type: EXPERIMENTAL): SOF+RBV for 16 weeks
- SOF+RBV 24 weeks (Type: EXPERIMENTAL): SOF+RBV for 24 weeks
- SOF+RBV+Peg-IFN 12 weeks (Type: EXPERIMENTAL): SOF+RBV+Peg-IFN for 12 weeks
- Retreatment Substudy (Type: EXPERIMENTAL): Participants from the SOF+RBV arms (16 weeks or 24 weeks) who experienced virologic failure on treatment, or during the posttreatment period at or before Posttreatment Week 24 may be eligible to enroll into the Retreatment Substudy to receive SOF+RBV+Peg-IFN for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).